Gaucherite - A Study to Stratify Gaucher Disease

Key facts

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Principal Investigator

Timothy M Cox, MD

University of Cambridge

Intervention

Stratified response to Enzyme Therapy(other)

Enrollment

250 enrolled

Eligibility

All sexes

Timeline

2014 – 2028

Study locations (8)

• Birmingham Childrens Hospital, Birmingham, United Kingdom
• New Queen Elizabeth Hospital, Birmingham, United Kingdom
• Cambridge University Hospital, Cambridge, United Kingdom
• Great Ormond Street Hospital, London, United Kingdom
• National Hospital for Neurology and Neurosurgery, London, United Kingdom
• Royal Free Hospital, London, United Kingdom
• Royal Manchester Childrens Hospital, Manchester, United Kingdom
• Salford Royal NHS Foundation Trust, Salford, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gaucher disease type 3

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNANCT07285369
  High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)
  Agyany Pharma LTD
• ENROLLING BY INVITATIONNANCT06627543
  Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3
  Noha Osman
• RECRUITINGNANCT06162338
  A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I
  He Huang
• RECRUITINGNANCT05586243
  MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
  University of Minnesota
• ACTIVE NOT RECRUITINGPHASE3NCT05222906
  Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
  Sanofi

See all trials for Gaucher disease type 3 →